Neuroblastoma 2

Common Name(s)

Neuroblastoma 2

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Neuroblastoma 2" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Neuroblastoma 2" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Neuroblastoma 2" returned 160 free, full-text research articles on human participants. First 3 results:

Upregulation of Human ST8Sia VI (α2,8-Sialyltransferase) Gene Expression by Physcion in SK-N-BE(2)-C Human Neuroblastoma Cells.
 

Author(s): Hyun-Kyoung Yoon, Hyun-Kyu An, Min Jung Ko, Kyoung-Sook Kim, Seo-Won Mun, Dong-Hyun Kim, Cheol Min Kim, Cheorl-Ho Kim, Young Whan Choi, Young-Choon Lee

Journal:

 

In this research, we firstly demonstrated that physcion, an anthraquinone derivative, specifically increased the expression of the human α2,8-sialyltransferase (hST8Sia VI) gene in SK-N-BE(2)-C human neuroblastoma cells. To establish the mechanism responsible for the up-regulation ...

Last Updated: 5 Aug 2016

Go To URL
Acrylamide affects proliferation and differentiation of the neural progenitor cell line C17.2 and the neuroblastoma cell line SH-SY5Y.
 

Author(s): K Attoff, D Kertika, J Lundqvist, S Oredsson, A Forsby

Journal: Toxicol In Vitro. 2016 Sep;35():100-11.

 

Acrylamide is a well-known neurotoxic compound and people get exposed to the compound by food consumption and environmental pollutants. Since acrylamide crosses the placenta barrier, the fetus is also being exposed resulting in a risk for developmental neurotoxicity. In this study, ...

Last Updated: 8 Jul 2016

Go To URL
Hexokinase 2 is a determinant of neuroblastoma metastasis.
 

Author(s): Liat Edry Botzer, Shelly Maman, Orit Sagi-Assif, Tsipi Meshel, Ido Nevo, Ilana Yron, Isaac P Witz

Journal: Br. J. Cancer. 2016 Mar;114(7):759-66.

 

Intersecting a genome-wide expression profile of metastatic and nonmetastatic human neuroblastoma xenograft variants with expression profiles of tumours from stage 1 and 4 neuroblastoma patients, we previously characterised hexokinase 2 (HK2) as a gene whose expression was upregulated ...

Last Updated: 30 Mar 2016

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Neuroblastoma 2" returned 1 free, full-text review articles on human participants. First 3 results:

The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma.
 

Author(s): Brett H Yamane, Jacquelyn A Hank, Mark R Albertini, Paul M Sondel

Journal: Expert Opin Investig Drugs. 2009 Jul;18(7):991-1000.

 

Patients with high risk melanoma and neuroblastoma frequently experience recurrence despite surgical resection and appropriate adjuvant therapies. Immunotherapy with the immunocytokine hu14.18-IL2 (EMD-273063) was developed by means of fusion of two molecules of IL-2 to the monoclonal ...

Last Updated: 24 Jun 2009

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma
 

Status: Recruiting

Condition Summary: Neuroblastoma

 

Last Updated: 9 Jan 2017

Go to URL
Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma
 

Status: Recruiting

Condition Summary: Neuroblastoma; High-Risk

 

Last Updated: 14 Sep 2016

Go to URL
Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma
 

Status: Recruiting

Condition Summary: Neuroblastoma; Effects of Immunotherapy

 

Last Updated: 9 Mar 2017

Go to URL